TC-002 Emerging Drug Insight

“TC-002, Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about TC-002 for Glaucoma in the 6MM (US and EU5). A detailed picture of the TC-002  for Glaucoma in the 6MM, i.e., the United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom for the study period 2019–2032 is provided in this report along with a detailed description of the TC-002  for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TC-002 market forecast, analysis for Glaucoma in the 6MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

 TC-002 is a preservative-free latanoprost ophthalmic solution that is being developed by TearClear for the treatment of glaucoma. TearClear is the first and only company to develop products that deliver preservative-free drops to the eye while maintaining BAK-preserved formulations in the bottle.

In September 2022, TearClear announced that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%), met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial. With these results, TearClear plans to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) in the first quarter of 2023. Upon approval, TC-002 will offer patients the first and only means of delivering preservative-free doses of latanoprost from conventional multi-dose bottles.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the TC-002 description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on TC-002 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the TC-002 research and development activity in Glaucoma in detail across the United States, and Europe.
•  The report also covers the patents information with expiry timeline around TC-002.
•  The report contains forecasted sales of TC-002 for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for TC-002 in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TC-002 Analytical Perspective by DelveInsight

• In-depth TC-002  Market Assessment

This report provides a detailed market assessment of TC-002 in Glaucoma in the 6MM, i.e., the US, and EU5 (Germany, France, Italy, Spain, and the United Kingdom). This segment of the report provides forecasted sales data from 2023 to 2032.

• TC-002  Clinical Assessment

The report provides the clinical trials information of TC-002 in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TC-002 dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to TC-002 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TC-002 in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of TC-002 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TC-002 in Glaucoma.

Key Questions

•  What is the product type, route of administration and mechanism of action of TC-002?
•  What is the clinical trial status of the study related to TC-002 in Glaucoma and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TC-002 development?
•  What are the key designations that have been granted to TC-002 for Glaucoma?
•  What is the forecasted market scenario of TC-002 for Glaucoma?
•  What are the forecasted sales of TC-002 in the six major countries, including the United States, and the Europe (Germany, France, Italy, Spain, and the United Kingdom)? 
•  What are the other emerging products available in Glaucoma and how are they giving competition to TC-002 for Glaucoma?
•  Which are the late-stage emerging therapies under development for the treatment of Glaucoma?